Could a common dewormer stop a rare, deadly liver parasite?
NCT ID NCT07182305
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tested the drug albendazole in 194 people with early-stage alveolar echinococcosis, a parasitic liver disease that is nearly always fatal within 10-15 years if untreated. Participants took albendazole twice daily and were monitored with ultrasound to see if their liver lesions shrank, calcified, or stopped growing. The goal is to see if early treatment can control the parasite and extend life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- albendazole
- What this could lead to
- If successful, this could confirm that early albendazole treatment controls the parasite and prevents disease progression, potentially allowing patients to live a normal lifespan.
- What could go wrong
- This is a small, completed Phase 2 trial in one region. Albendazole is parasitostatic, not curative, and lifelong treatment may be needed. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR ECHINOCOCCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of disease prevention and sanitary - epidemiological surveillance
Bishkek, Kyrgyzstan